Amgen Inc. $AMGN Stock Acquired by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 3.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 60,996 shares of the medical research company’s stock after purchasing an additional 2,230 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Amgen were worth $25,710,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AMGN. Confluence Wealth Services Inc. grew its position in Amgen by 7.8% in the 3rd quarter. Confluence Wealth Services Inc. now owns 18,976 shares of the medical research company’s stock worth $7,998,000 after purchasing an additional 1,376 shares during the last quarter. Moneco Advisors LLC raised its position in shares of Amgen by 5.5% during the third quarter. Moneco Advisors LLC now owns 4,643 shares of the medical research company’s stock valued at $1,957,000 after buying an additional 242 shares during the last quarter. Mesirow Financial Investment Management Inc. raised its position in shares of Amgen by 2.3% during the third quarter. Mesirow Financial Investment Management Inc. now owns 14,846 shares of the medical research company’s stock valued at $6,258,000 after buying an additional 328 shares during the last quarter. Woodley Farra Manion Portfolio Management Inc. raised its position in shares of Amgen by 4.1% during the third quarter. Woodley Farra Manion Portfolio Management Inc. now owns 15,509 shares of the medical research company’s stock valued at $6,537,000 after buying an additional 613 shares during the last quarter. Finally, 626 Financial LLC bought a new stake in shares of Amgen in the third quarter valued at about $222,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. William Blair reissued an “outperform” rating on shares of Amgen in a research report on Wednesday, November 4th. Sanford C. Bernstein upped their price target on Amgen from $345.00 to $400.00 and gave the company a “market perform” rating in a report on Wednesday, November 4th. Oppenheimer reiterated an “outperform” rating on shares of Amgen in a research report on Friday, October 23rd. Weiss Ratings raised Amgen from a “buy (b)” rating to a “buy (b+)” rating in a report on Thursday, October 8th. Finally, Morgan Stanley lifted their price objective on Amgen from $359.00 to $410.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $422.76.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New data presented at the American Heart Association’s 2026 Scientific Sessions strengthened the case for earlier and more intensive Repatha treatment. Amgen cited an analysis finding the drug highly cost-effective in high-risk patients without a prior heart attack or stroke, and a long-term analysis associating it with a 29% lower risk of major cardiovascular events in patients with existing cardiovascular disease. These findings could support Repatha’s clinical profile and adoption, although the reported evidence includes an external-control analysis. Read article
• Neutral Sentiment: Investors are watching for ACR conference data on dazodalibep. The coverage frames the results as a test for the program, but the provided reports do not disclose findings, so the clinical and stock impact remains uncertain. Read article
• Neutral Sentiment: Recent coverage also compares Amgen’s dividend income and valuation with Regeneron’s faster growth, while another report says analyst views on Amgen are mixed. Neither item provides a specific new forecast or rating change that clearly shifts the near-term outlook. Read article

Insider Activity at Amgen

In related news, SVP Rachna Khosla sold 1,252 shares of the business’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the sale, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,666,817.72. The trade was a 16.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.85% of the stock is owned by company insiders.

Amgen Stock Performance

NASDAQ:AMGN opened at $465.23 on Wednesday. The firm has a market capitalization of $251.65 billion, a PE ratio of 26.99, a price-to-earnings-growth ratio of 3.25 and a beta of 0.43. The company has a quick ratio of 1.20, a current ratio of 1.48 and a debt-to-equity ratio of 3.60. Amgen Inc. has a 12-month low of $312.39 and a 12-month high of $483.99. The firm has a 50-day moving average price of $423.79 and a 200 day moving average price of $379.39.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The company had revenue of $10.37 billion for the quarter, compared to the consensus estimate of $10.07 billion. During the same period in the previous year, the business earned $5.64 earnings per share. The company’s quarterly revenue was up 8.5% on a year-over-year basis. Research analysts anticipate that Amgen Inc. will post 23.33 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Friday, November 20th. Amgen’s dividend payout ratio (DPR) is 58.47%.

Amgen Profile

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.